- Magazine
- News
- Articles
- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Genomics
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Lyophilisation
- Microbiology & RMMs
- NIR, PAT & QbD
- Proteomics
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Toxicology
- Blog
- Whitepapers
- Videos
- Webinars
- Events & Workshops
- Directory
Patents - Articles and news items
Shire wins Lialda patent trial against Watson
Industry news / 29 March 2016 / Victoria White
The US District Court for Southern Florida has upheld Shire’s patent for Lialda (mesalamine) delayed release tablets for adults with ulcerative colitis…
Allergan files ANDA to the FDA for generic Abraxane
Industry news / 17 March 2016 / Victoria White
Allergan believes it is a first applicant to file an ANDA for generic Abraxane and, should it be approved, may get 180 days of generic market exclusivity…
The cost of drug counterfeiting
Issue 1 2015 / 10 March 2015 / David Elder, GlaxoSmithKline and JPAG
The World Health Organisation (WHO) in 2010 described counterfeit medicines as those which are “Deliberately and fraudulently mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded and generic products and counterfeit products may include products with the correct ingredients or with the wrong ingredients, without active ingredients, with insufficient active ingredients or with fake packaging.” The WHO also now uses the term ‘spurious/falsely labelled/falsified/counterfeit (SFFC) medicines’. In addition, there is the related phenomenon of sub-standard medicines, classified by the WHO as: “Genuine medicines produced by manufacturers authorised by the National Medicines Regulatory Authority (NMRA), which do not meet quality specifications set for them by national medicines.” Most of these counterfeit/imitation medicines are manufactured in Asia (predominantly India and China) and Latin America, where patents carry little weight, enforcement agencies are lax and there is a cheap, abundant workforce…
Kuros announces grant of US patent for its synthetic hydrogel technology
Industry news / 24 February 2015 / Kuros
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947…
Patent cliff means pharmaceutical companies will lose $65 billion by 2019, says GlobalData
Industry news / 11 December 2014 / GlobalData
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData…
The future of ‘Patent Boxes’ – the OECD’s adoption of a joint proposal by UK and Germany
Industry news / 4 December 2014 / Deloitte
In a written ministerial statement issued, the Financial Secretary to the Treasury, Mr David Gauke, confirmed that the Organisation for Economic Cooperation and Development (OECD) has adopted all of the proposals…
Teva announces UK High Court gives positive judgment in the company’s patent case against AstraZeneca
Industry news / 3 September 2014 / Teva
Court decision invalidating AZ’s patent supports Teva’s launch of DuoResp Spiromax® in UK…
is it ever right to sue a client?
Issue 2 2011, Patents / 19 April 2011 / Jim Kinnier Wilson, Partner, Manches
Imagine that you are part of a small biotech company, BiotechCo, whose business is the development of delivery systems for pharmaceutical products. One of your team, who is in charge of developing sales with a large pharmaceutical company, Pharma Co, came to you three months ago with the possibility of a very interesting contract within that company. You went to a meeting where various things were discussed on a confidential basis. As a result of that, you now have a clearer idea of where the pharmaceutical company is aiming to take an important drug, which is approaching the end of its patent life. If BiotechCo can come up with a new improved delivery system, then you will assist Pharma Co in creating a significant market lead for their drug, and by so doing probably increase the chances of selling your portfolio of technologies to Pharma Co. You have set your best research brains on to the problem, and they have come up with a very clever device which uses technology that has been known outside the pharmaceutical sector for a non-medical purpose. Their developments have been reported to Pharma Co on a confidential basis and Pharma Co has been given a prototype. Pharma Co has done some tests on the device.